

Oxurion Receives Transparency Notifications from Negma Group

Leuven, BELGIUM, Boston, MA, US – December 19, 2022 – 7.00 PM CET [Oxurion NV](#) (Euronext Brussels: OXUR) a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, today announced that, pursuant to Belgian Transparency legislation¹ it has received transparency notifications as follows:

Oxurion received transparency notification on December 15 from Negma Group Ltd. indicating that as of December 9, it held 99,789,915 shares of the then outstanding 411,071,559 shares, and therefore crossed above the 20% threshold by virtue of acquisition of voting securities. See Annex 1

About Oxurion

Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing next generation standard of care ophthalmic therapies, which are designed to improve and better preserve vision in patients with retinal disorders including diabetic macular edema (DME), the leading cause of vision loss in working-age people, as well as other conditions. Oxurion intends to play an important role in the treatment of retinal disorders, including the successful development of THR-149, its novel therapeutic for the treatment of DME. THR-149 is a potent plasma kallikrein inhibitor being developed as a potential new standard of care for the up to 50% of DME patients showing suboptimal response to anti-VEGF therapy. Oxurion is headquartered in Leuven, Belgium, with corporate operations in Boston, MA. More information is available at www.oxurion.com.

Important information about forward-looking statements

Certain statements in this press release may be considered “forward-looking”. Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company’s Annual Report. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of Oxurion in any jurisdiction. No securities of Oxurion may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.

For further information please contact:

Oxurion NV Tom Graney Chief Executive Officer Tel: +32 16 75 13 10 tom.graney@oxurion.com	US Conway Communications Beth Kurth bkurth@conwaycommsir.com
---	---

Michael Dillen
Chief Business Officer

Tel: +32 16 75 13 10

michael.dillen@oxurion.com

ICR Westwicke

Christopher Brinzey

Tel: +1 617 835 9304

Chris.Brinzey@westwicke.com

1. Article 14, first paragraph, of the Law of 2 May 2007 on disclosure of major holdings.

ANNEX 1

1) Status of the notification

Final

2) Issuer

Name: **OSURION**
 Identification number: **0881-620-0204**

3) Reason for the notification

Acquisition or disposal of voting securities or voting rights

4) Notification by

A parent undertaking or a controlling person

5) Persons subject to the notification requirement

Name	Address (for legal entities)
Elaf Gassam	
Nagma Group Investment Ltd.	Unit 1 Level 26, ICD Brookfield Place, DIFC, Dubai (United Arab Emirates)
Nagma Group Ltd.	Craigmar chambers, Road Town, Tortola, VG 1110 (British Virgin Islands)

6) Persons that dispose of voting rights (only to be filled in if art. 7 of the Law applies)

Name	Address (for legal entities)

Please continue entering the information in **part II** concerning the persons referred to in Sections 5 and 6

Part II

7) Date on which the threshold is crossed

09/12/2022 (DDMMYYYY)

8) Threshold that is crossed (in %)

20

If the holding has fallen below the lowest threshold, you have the option of not entering any numbers in Section 10

9) Denominator


411,071,599

Please enter the denominator before filling in the data


10) Notified details

A) Voting rights	Previous notification	After the transaction			
	# of voting rights	# of voting rights		% of voting rights	
Holder of voting rights		Linked to securities	Not linked to the securities	Linked to securities	Not linked to the securities
Elaf Gassam	0	0		0.00%	
Nagma Group Investment Ltd.	0	0		0.00%	
Nagma Group Ltd.	1,837,132	99,789,915		24.28%	
Subtotal	1,837,132	99,789,915		24.28%	

TOTAL	99,789,915	0	24.28%	0.00%
-------	------------	---	--------	-------

 Start with "groups" of holders. Add subtotals with Σ , and then finish with the persons who are "alone".
For groups, start with the ultimate controlling natural person or legal entity.
The totals, subtotals and % will be updated once you have clicked on **<CALCULATE>**.

B) Equivalent financial instruments	After the transaction						
	Holders of equivalent financial instruments	Type of financial instrument	Expiration date	Exercise period or date	# of voting rights that may be acquired if the instrument is exercised	% of voting rights	Settlement
					0	0.00%	
TOTAL					0	0.00%	

 The totals will be updated once you have clicked on <CALCULATE>

TOTAL (A & B)	# of voting rights	% of voting rights
	99,789,915	24.28%

CALCULATE

11) Full chain of controlled undertakings through which the holding is effectively held, if applicable

Nagma Group Ltd. is controlled by Nagma Group Investment Ltd. (Unit 1 Level 25, 100 Brookfield Place, DIFC, Dubai, UAE - Company number: CL5377), who in its turn is controlled by Elaf Gassen (private individual).

12) In case of proxy voting for only one GM

Holder will cease to hold / will hold again voting rights as of (DDMMYYYY)

13) Additional information

Done at Dubai, United Arab Emirates

On 15/12/2022 (DDMMYYYY)

Name & capacity Elaf Gassen, Director

Signature